Support Alert

Drug safety update: Naltrexone/bupropion (Mysimba)

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug safety update that patients should be advised that naltrexone/bupropion has been associated with adverse reactions such as dizziness or somnolence, which can affect ability to drive, operate machinery, or perform dangerous tasks. Advise patients not to drive if they suspect their ability may be impaired. 


Some of our content, including support alerts, is only available to RPS members. 

Log in

Find out more about membership of the Society

Loading...